Physiologically based pharmacokinetic modelling and simulation to predict the plasma le of schaftoside after oral administration of total avonoids of

HIGHLIGHTS

SUMMARY

Previous studies indicated that schaftoside could protect against cholesterol gallstone and calcium_oxalate kidney stone formation (Liu et_al, 2017; Liu et_al, 2020). By integrating population-specific physiologic parameters with drug-specific physicochemical and pharmacokinetics information, PBPK models are increasingly used for the prediction of drug distribution, drug-drug interactions (DDI), transporter evaluation, and extrapolation of drug exposure in age-specific or special subgroups of patients (Jones et_al, 2009; Maharaj and Edginton, 2014; ReigLopez et_al, 2021). The prevalence rate of urolithiasis is approximately 5-9% in Europe, 12-15% in North America, and 1-5% in . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.